EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antiobesity Pharmacotherapy for Patients With Genetic Obesity Due to Defects in the Leptin-Melanocortin Pathway

Mila S Welling iD, Elisabeth F C van Rossum iD, Erica L T van den Akker iD

Endocrine Reviews · 09.05.2025 · 46 (3) · 418-446

DOI: 10.1210/endrev/bnaf004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrine Reviews, online erschienen am 11.02.2025. Verfasst von Mila S Welling und 2 weiteren Autor:innen. Beteiligte Einrichtung: Obesity Center CGG, Erasmus MC, University Medical Center Rotterdam, Rotterdam 3015 GD, The Netherlands. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Obesity, Leptin, Melanocortins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 190 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lifestyle interventions are the cornerstone of obesity treatment. However, insufficient long-term effects are observed in patients with genetic obesity disorders, as their hyperphagia remains untreated. Hence, patients with genetic obesity often require additional pharmacotherapy to effectively manage and treat their hyperphagia and obesity. Recent advancements in antiobesity pharmacotherapy have expanded the range of available antiobesity medications (AOM). This includes the targeted AOM setmelanotide, approved for specific genetic obesity disorders, as well as nontargeted AOMs such as naltrexone-bupropion and glucagon-like peptide-1 analogues. Targeted AOMs have demonstrated significant weight loss, reduced obesity-related comorbidities, and improved hyperphagia and quality of life in patients with specific genetic obesity disorders. Small observational studies have shown that similar benefits from nontargeted AOMs or off-label pharmacotherapies can be achieved in patients with specific genetic obesity disorders, compared to common multifactorial obesity. In the future, novel and innovative pharmacotherapeutical options, including combination therapies and possibly gene therapy, will emerge, offering promising effects on body weight, hyperphagia, and, most importantly, quality of life for patients with a variety of genetic obesity disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Obesity AgentsObesityLeptinMelanocortinsHumansSignal Transduction

Stichwörter der Autor:innen

AOManti-obesity medicationgene therapygeneticsnon-targetedobesitytargeted

Substanzen

Anti-Obesity AgentsLeptinMelanocortins

Autor:innen und Institutionen

  • Obesity Center CGG, Erasmus MC, University Medical Center Rotterdam, Rotterdam 3015 GD, The Netherlands.
  • Department of Internal Medicine, Division of Endocrinology, Erasmus MC, University Medical Center Rotterdam, Rotterdam 3015 GD, The Netherlands.
  • Department of Pediatrics, Division of Endocrinology, Erasmus MC-Sophia Children's Hospital, University of Medical Center Rotterdam, Rotterdam 3015 GD, The Netherlands.

ORCID-Profile: Mila S Welling, Elisabeth F C van Rossum, Erica L T van den Akker

Zitieren

APA

Welling, M. S., van Rossum, E. F. C., & van den Akker, E. L. T. (2025). Antiobesity Pharmacotherapy for Patients With Genetic Obesity Due to Defects in the Leptin-Melanocortin Pathway. Endocrine Reviews, 46(3), 418-446. https://doi.org/10.1210/endrev/bnaf004

Vancouver

Welling MS, van Rossum EFC, van den Akker ELT. Antiobesity Pharmacotherapy for Patients With Genetic Obesity Due to Defects in the Leptin-Melanocortin Pathway. Endocrine Reviews. 2025;46(3):418-446. doi:10.1210/endrev/bnaf004

BibTeX
@article{Welling2025,
  author = {Welling, Mila S and van Rossum, Elisabeth F C and van den Akker, Erica L T},
  title = {Antiobesity Pharmacotherapy for Patients With Genetic Obesity Due to Defects in the Leptin-Melanocortin Pathway},
  journal = {Endocrine Reviews},
  year = {2025},
  volume = {46},
  number = {3},
  pages = {418--446},
  doi = {10.1210/endrev/bnaf004}
}
Kostenlos starten →